vTv Therapeutics (NASDAQ:VTVT – Get Free Report) was upgraded by analysts at Lifesci Capital to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.
VTVT has been the subject of a number of other research reports. Wall Street Zen lowered vTv Therapeutics from a “buy” rating to a “sell” rating in a report on Saturday, August 8th. Zacks Research lowered vTv Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Weiss Ratings downgraded vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Rodman & Renshaw started coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price objective for the company. Finally, HC Wainwright decreased their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, vTv Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.83.
Check Out Our Latest Research Report on vTv Therapeutics
vTv Therapeutics Stock Performance
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). On average, research analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of VTVT. 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics in the 4th quarter valued at $731,000. Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics during the fourth quarter worth $221,000. Finally, Geode Capital Management LLC increased its position in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.
The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.
Read More
- Five stocks we like better than vTv Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
